Study of Novel Radioenhancer NBTXR3 Plus Radiotherapy in Patients With Locally Advanced Soft Tissue Sarcoma: Results of the Long-Term Evaluation in the Phase II/III Act.In.Sarc Trial

S Bonvalot,P Rutkowski, J O Thariat, S Carrere, A Ducassou, M P Sunyach,P Ágoston, A Hong, A Mervoyer, M Rastrelli,C Le Pechoux,V Moreno,R Li, B Tiangco, Z Papai

International Journal of Radiation Oncology*Biology*Physics（2021）

引用 0|浏览3

暂无评分

摘要

These results demonstrate that the use of NBTXR3 did not change the late onset toxicity profile of EBRT, nor modified its bystander effect. Taken together, the long-term safety data presented here, and the previously published efficacy data reinforce the favorable benefit-risk ratio of the use of NBTXR3 in patients with LA STS. NCT02379845.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要